Arthritis Drugs and Lymphoma Risk
The arthritis drugs known as TNF-blockers do not seem to markedly increase the chances of developing malignant lymphoma, according to the results of a Swedish study.
TNF is a natural inflammatory compound that was originally identified as an anti-tumor substance. While blocking TNF often greatly improves rheumatoid arthritis, there has been concern that doing so might allow cancers to develop.
Dr. J. Askling of the Karolinska University Hospital and colleagues used data from two large Swedish registries to identify nearly 68,000 patients with rheumatoid arthritis. Of these subjects, about 6600 started anti-TNF therapy between 1998 and 2006.
Malignant lymphomas occurred in 26 patients on anti-TNF therapy and in 336 of those not treated with these agents, the researchers report in the Annals of the Rheumatic Diseases.
They calculate that the risk of developing malignant lymphoma was 1.35-fold higher for rheumatoid arthritis patients given TNF-blockers compared to those who were not.
SOURCE: Annals of the Rheumatic Diseases, May 2009.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
